Document is current
Any future updates will be listed below
-
Authors
Tanaka, Sakae https://orcid.org/0000-0001-9210-9414
Uemura, Yukari
Tanaka, Shiro
Takeuchi, Yasuhiro
Endo, Naoto
Takada, Junichi
Ikeda, Satoshi
Iwamoto, Jun
Okimoto, Nobukazu
Soen, Satoshi
-
Funding
Funding for this research was provided by:
Public Health Research Foundation
Asahi Kasei Pharma Corp.
The University of Tokyo
- License Information
-
More Information
Article History
Received: 3 July 2025
Accepted: 29 July 2025
First Online: 3 September 2025
Declarations
:
: S Tanaka has received lecture fees from Teijin Pharma Ltd., Asahi Kasei Pharma Corp., Amgen Inc., and Daiichi Sankyo Co., Ltd., and research grants from Teijin Pharma Ltd., Asahi Kasei Pharma Corp., Daiichi Sankyo Co., Ltd., and Chugai Pharmaceutical Co., Ltd. Y Uemura has received speaking fees from Eli Lilly Japan Co., Ltd. She has received consulting fees from Amgen Inc., and research grants from the Japan Agency for Medical Research and Development. Shi Tanaka has received lecture fees from the Research Institute of Healthcare Data Science. He has received consultation fees and outsourcing fees from Eli Lilly and Company, Welby, Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K., Satt, and the Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development, the Japanese Ministry of Health, Labour and Welfare, the Japanese Ministry of Education, Science and Technology, and Novo Nordisk. He engaged in a research project of the Japan Agency for Medical Research and Development. Y Takeuchi has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mochida Pharma Co., Ltd., Kyowa Kirin Co., Ltd., Alexion Pharma GK., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sumitomo Pharma Co., Ltd., Recordati Rare Diseases Japan K.K., Mitsubishi Tanabe Pharma Corporation, JCR Pharmaceuticals Co., Ltd., Kowa Pharmaceutical Co., Ltd., ASKA Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. N Endo has received lecture fee, speaking fee from UCB Japan Co., Ltd, Kyowa Kirin Co., Ltd., and Tsumura & Co. J Takada has received consulting fees and speaking fees from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Kaken Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. S Ikeda has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Pfizer Inc., Hisamitsu Pharmaceutical Co., Inc., Mochida Pharma Co., Ltd., Teijin Pharma Ltd., Towa Pharmaceutical Co., Ltd., and UCB Japan Co., Ltd. J Iwamoto has received speaking fees from Asahi Kasei Pharma Corp., Eisai Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Teijin Pharma Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kaken Pharmaceutical Co., Ltd., Amgen Inc., Astellas Pharma Inc., and Towa Pharmaceutical Co., Ltd. N Okimoto has received payments for lectures, including speakers’ bureau fees from Asahi Kasei Pharma Corp., Amgen Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan, and Teijin Pharma Ltd. S Soen has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd.
